Parkinson's disease (PD) is an age-related neurodegenerative disorder affecting approximately 5% of people over age 65. PD is characterized pathologically by the selective degeneration of dopaminergic neurons in the substantia nigra and the formation of intraneuronal inclusions known as Lewy bodies. Existing animal models of PD produce alterations in dopaminergic neurons through genetic or toxic manipulations that may not be relevant to the pathophysiology of PD. We therefore propose to study the molecular pathogenesis of PD through the production of mice bearing genetic modifications that have been implicated in familial PD. The central hypothesis underlying our research is that mutations in the alpha-synuclein gene, recently linked to early-onset familial PD, alter the normal physiology of dopaminergic neurons in the substantia nigra, ultimately leading to their degeneration and production of the parkinsonian phenotype. First, we hypothesize that mutations in alpha-synuclein linked to familial PD (FPD) alter its normal function, resulting in the formation of Lewy bodies and degeneration of dopaminergic neurons. To understand the pathogenicity of mutations in alpha-synuclein, we propose to generate animal models of FPD using transgenic and khockin mice expressing mutant forms of human alpha-synuclein. Second. The alpha-synuclein mutant mice will then be analyzed for biochemical and neuropathological abnormalities associated with PD, such as degeneration of doparninergic neurons and reductions in striatal dopamine levels.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
1P50NS038375-01A1
Application #
6259568
Study Section
Special Emphasis Panel (ZNS1-SRB-K (01))
Project Start
1999-09-30
Project End
2004-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Bartels, Tim; Choi, Joanna G; Selkoe, Dennis J (2011) ýý-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477:107-10
Shtifman, Alexander; Zhong, Nan; Lopez, Jose R et al. (2011) Altered Ca2+ homeostasis in the skeletal muscle of DJ-1 null mice. Neurobiol Aging 32:125-32
Vamvaca, Katherina; Lansbury Jr, Peter T; Stefanis, Leonidas (2011) N-terminal deletion does not affect ýý-synuclein membrane binding, self-association and toxicity in human neuroblastoma cells, unlike yeast. J Neurochem 119:389-97
Berger, Zdenek; Smith, Kelsey A; Lavoie, Matthew J (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49:5511-23
Giaime, E; Sunyach, C; Druon, C et al. (2010) Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6. Cell Death Differ 17:158-69
Logan, Todd; Clark, Lindsay; Ray, Soumya S (2010) Engineered disulfide bonds restore chaperone-like function of DJ-1 mutants linked to familial Parkinson's disease. Biochemistry 49:5624-33
Tong, Youren; Shen, Jie (2009) alpha-synuclein and LRRK2: partners in crime. Neuron 64:771-3
da Costa, Cristine Alves; Sunyach, Claire; Giaime, Emilie et al. (2009) Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 11:1370-5
Rappley, Irit; Gitler, Aaron D; Selvy, Paige E et al. (2009) Evidence that alpha-synuclein does not inhibit phospholipase D. Biochemistry 48:1077-83
Cronin, Kenneth D; Ge, Dongliang; Manninger, Paul et al. (2009) Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet 18:3274-85

Showing the most recent 10 out of 41 publications